Atopic dermatitis AD is a chronic inflammatory skin disease. Patients with AD have increased infection risk including skin infections and systemic infections. Dupilumab a fully human monoclonal antibody blocks the shared receptor component for interleukin-4 IL-4 and IL-13. Dupilumab is approved for inadequately controlled moderate-to-severe AD.1. No evidence of increased risk for COVID-19 infection in patients treated with Dupilumab for atopic dermatitis in a high-epidemic area - Bergamo Lombardy Italy.